CTSA Coordination, Communication, & Operations Support

October 26, 2026
2:30-3:30pm ET

Steering Committee Meeting

digital Infuzion® Deloitte. ICF University of Rochester Medicine

Agenda

Time	Topic	Speaker(s)
2:30pm – 2:35pm	Welcome & Announcements - WG Extension: LHS-CTSA Partnerships	Michael Kurilla Grace McComsey Amanda Scott
2:35pm- 2:55pm	Annual K Report Out	Dominic Reeds
2:55pm – 3:15pm	WG Report Out: Translational Case Studies in Commercialization	Andrew Kant, Erin Carey, Shawn Gomez
3:15pm – 3:30pm	Pod Spotlight: Stanford Center for Clinical & Translational Education and Research (Spectrum)	Manisha Desai
3:30pm	Adjourn	

Vote: LHS-CTSA Partnerships



Survey Link: WG Extension: LHS-CTSA Partnerships 20261026 – Fill out form

CTSA Coordination, Communication, & Operations Support

Presented By: Dominic Reeds

Annual K Report Out

digital Infuzion® Deloitte. ICF University of Rochester Medicine

KL2/K12 Update

Dominic Reeds, MD

Nutritional Science and Obesity Medicine

Director, Washington University KL2 Program

Professor of Medicine

Associate Dean for Research, Goldfarb School of Nursing



Who are we?

KL2/K12 PIs

Meet every other month (alternate with T32/R25 PIs)

Meetings attended by 70-80 members

Leadership Team drives the agenda

- 4 KL2/K12 PIs

Informal face to face meeting at CTSA and NCATS meetings

Goals

- Support training for K Scholars
- Ensure best-practices in Mentoring
- Support networking across programs
- Recruit and train high-quality scholars
- Support national exposure opportunities for scholars and site PIs
- Work with NCATS to identify and answer questions regarding the K12 programs and scholars

Opportunities and Activities

- Peers Investing in Each Other
  - Peer Inquiry, Reflection, and Engagement (INSPIRE)
  - Peer coaching triads
  - Topical group coaching sessions (e.g., core values, sponsorship)
  - Integrated into existing K programming
- K and T Visiting Scientists Consortium Group
  - Discuss translational science concepts in Scholars' research talks.
  - Scholars identify up to 3 Hubs and 3 faculty experts with rationale for meeting

University of Pittsburgh NIGMS 5R01GM155395

Activities

- Meeting with Dr. Kurilla to address site concerns/questions regarding scholar reappointment for 2nd year
- Dr. Krasnova and Dr. Brown meeting: **Scholar Eligibility and Appointment Requirements and Considerations**
- What'sApp chat group engaging ~50 site PIs
- Meetings of KL2/K12 PIs at CTSA and NCATS symposiums
  - Mentoring best practices
  - Scholar progression
  - Networking
  - Scholar selection strategies

Concerns

- Potential for delay in funding for K23/K08
- Small research budgets
- Administrative burden
- Salary Cap
- Loss of scholars to clinical medicine
- Changes in policy on clinical/feasibility trials

CTSA Coordination, Communication, & Operations Support

Presented By: Andrew Kant, Erin Carey, Shawn Gomez with Dominic Reeds and Manisha Desai

Translational Case Studies in Commercialization

digital Infuzion® Deloitte. ICF University of Rochester Medicine

Translational Case Studies in Commercialization (TCSC)

CTSA Steering Committee

North Carolina Translational and Clinical Sciences (NC TraCS) Institute



What helps discoveries progress, and where do they stall?

U.S. academic technology transfer in 2024

26,196

invention disclosures received

775

new products created

Annual totals across technologies; these are not a tracked cohort or a conversion rate.

For new drugs, discovery to approval averages about 14 years.

Sources: AUTM 2024 U.S. Licensing Survey; NCATS, New Therapeutic Uses

TCSC Scope and Comparative Approach

Purpose

Understand commercialization trajectories and identify recurring barriers and better practices.

Design

Two cases per participating hub: a successful and a challenged effort, examined through multiple stakeholder perspectives.

Core deliverables

Standardized framework and case repository; cross-case analysis and JCTS manuscript.



Progress and Remaining Work

Completed

Case study framework, case interviews complete; first/second-cycle coding pilot coding; AI-assisted qualitative coding workflow.

Underway

Codebook refinement with human validation and full case coding.

Next


Complete comparative analysis and prepare the case repository and JCTS manuscript for dissemination.

Themes Emerging

- **Institutional support can also create obstacles.** The same policies and resources that enabled commercialization sometimes introduced delays, deferred difficult negotiations, or created competing institutional interests.
- **People, time, and credibility were central constraints.** Progress depended on dedicated effort, trusted mentors, individual champions, and founders' ability to attract partners and investment. The science itself was rarely identified as the primary obstacle.
- **Funding gaps remain as ventures moved toward scale-up.** Early support helped launch companies, but larger development and clinical costs exposed financing gaps—even after institutional hurdles had been cleared.
- **Different stakeholders revealed different parts of the journey.** Inventors, company leaders, and institutional support providers offered complementary accounts, reinforcing the importance of multiple perspectives within each case.

AI-Assisted Outcome Tracing

Emerging WG contribution: UMN (Sandra Wells) tool traces milestones from public records.



Potential: longitudinal CTSA outcome tracking with targeted institutional verification.

Looking Ahead | Commercialization as Translational Science

Apply systems-thinking methods: Examine how institutional policies, expertise, and funding interact to accelerate or delay translation.

Develop better measures of progress: Capture intermediate milestones, delays, and consequential decisions alongside longer-term commercialization outcomes.

Enable prospective learning across hubs: Use case-study findings to guide shared data collection and test approaches to improving translational progress.

Outputs, Next Milestones, and Committee Input

Additional outputs

2026 ACTS poster; CCIA grant submission on commercialization competencies; ACTS SIG proposed, 2027 ACTS panel proposal submitted.

Next milestones

Finalize comparative analysis and draft JCTS manuscript.



The University
of North Carolina
at Chapel Hill

Appendix: Working Group Membership



27 members across 16 CTSA institutions

Appendix: Case Selection Criteria

Successful effort: at least one

License in good standing or significant commercial partnership

Startup with significant product development

Product launch with market entry, revenue, or patient adoption

Clinical trials or approval showing clinical utility or patient benefit

Revenue or path to profitability

Broad uptake or adoption

Challenged effort: at least one

Abandonment due to technical, financial, regulatory, or market challenges


Stagnation of at least 3 years without tangible commercial progress or funding milestones

Loss of critical partnerships or funding

Partial progress that did not result in scalable impact or adoption

MULTI-STAKEHOLDER PERSPECTIVES

Each commercialization case is examined through the eyes of the people who lived it — capturing the full arc of decisions, dynamics, and turning points across every role in the innovation ecosystem.



CTSA Coordination, Communication, & Operations Support

Presented By: Manisha Desai

Pod Spotlight: Stanford Center for Clinical & Translational Education and Research (Spectrum)

digital Infuzion® Deloitte. ICF University of Rochester Medicine

Next Meeting: November 9, 2026

Agenda:

- Pod Spotlight: Mayo Clinic
- WG Report Out: Learning about the Science of Translation
- NCATS Survey



**If you are unable to attend a meeting, please inform us at steeringcmte@ccos.ctsa.io. Slides and summaries will be made available post-meeting. Substitutions are not permitted for Steering Committee meetings.*